- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06938412
Oefeningactiviteitsinterventie met op sensor gebaseerde betrokkenheid bij patiënten met atriumfibrillatie (EASE-AF)
Oefeningactiviteitsinterventie met op sensor gebaseerde betrokkenheid bij patiënten met atriumfibrillatie (gemak-AF)
Atrial fibrillation (AF) affects 1 in 4 individuals during their lifetime and continues to increase in frequency and impact. Exercise intervention has established benefits to improve AF symptoms and burden in clinical studies. However, lack of access to exercise programs has limited therapeutic adoption. The growth of technology-driven health care and diagnostics, recognized as an emerging priority by the American Heart Association, offers an opportunity for a pragmatic and patient-centered approach to meet this need. EASE-AF is a prospective, interventional study with a sequential run-in control to evaluate if a digital health-driven, patient-centered exercise intervention improves AF symptoms and burden. The research team will enroll 120 patients with symptomatic, non-permanent AF. The main impact of this study will be the establishment of evidence for a novel, pragmatic paradigm for a patient-centered, digital technology-driven personalized exercise intervention for patients with AF.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Jaclyn Printz
- Telefoonnummer: 917-991-674
- E-mail: EASE-AF@mountsinai.org
Studie Contact Back-up
- Naam: Jaclyn Printz
- Telefoonnummer: 212-824-7077
- E-mail: Jaclyn.Printz@mountsinai.org
Studie Locaties
-
-
New York
-
New York, New York, Verenigde Staten, 10029
- Werving
- Icahn School of Medicine at Mount Sinai
-
Hoofdonderzoeker:
- Janice Y Chyou, MD
-
Contact:
- Jaclyn Printz
- E-mail: EASE-AF@mountsinai.org
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- ≥40years of age
- non-permanent AF
- Electrocardiographic (or equivalent) documentation of AF within 36 months (would need to have evidence of AF after initial post-ablation blanking period if the patient had prior AF ablation)
- AF Severity Scale (AFSS) symptom score 6-26
- Self-report weekly moderate-vigorous physical activity (MVPA) < 150 minutes
Exclusion Criteria:
- Unable to give consent
- ≤90 days from AF ablation, coronary revascularization, heart failure hospitalization
- Left ventricular ejection fraction (LVEF) <40%, moderate to severe stenotic valvular heart disease or severe regurgitant valvular disease or history of mechanical valve replacement, presence of implanted pacemaker or defibrillator system
- Labile INR or unable to take anticoagulant despite indication
- Life expectancy < 1 year
- Hemodialysis; severe pulmonary or liver disease
- Musculoskeletal, balance/gait issues, severe peripheral vascular disease, or neuropathy or other neurologic conditions limiting exercise
- Upon initial screening, if the participant's baseline FitBit-measured MVPA ≥180 minutes/week (despite self-report range of <150 minutes), the participant will be further excluded.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Patients With Atrial Fibrillation
Patients with symptomatic, non-permanent AF. |
The intervention is a digital technology-driven, patient-centric approach to physical activity and exercise intervention with tailored digital engagement and progressive physical activity goals (the intervention). The intervention will be conducted using FitBit wearable device. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Atrial Fibrillation Severity Scale (AFSS), Symptom Severity Domain
Tijdsspanne: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
The Symptom Severity domain (Part C) of the validated Atrial Fibrillation Severity Scale (AFSS) questions patients regarding the severity of 7 AF-related symptoms (on scale of 0-5 per question, 5 denoting a great deal of symptom and 0 with no symptom) over the preceding 4-week period. Total scores range 0-35 on the Symptom Severity Domain of the Atrial Fibrillation Severity Scale (AFSS), higher score denotes more severe AF-related symptoms. |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Atrial Fibrillation Severity Scale (AFSS)
Tijdsspanne: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
The full Atrial Fibrillation Severity Scale (AFSS) is composed of 19-items, investigating four domains: global well-being, symptom burden, health care utilization, symptom severity. Global well-being: 1-10; 10 denotes best possible quality of life. Symptom burden: Composite of AF burden as AF duration + AF frequency + AF severity; ranging 0-30, higher denotes more symptom burden. Health care utilization: ER visits (0-7, higher number denotes more utilization), Hospitalizations (0-7, higher number denotes more utilization), Specialist visits (0-7, higher number denotes more utilization); Symptom Severity: 0-35, higher score denotes more severe AF-related symptoms |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
|
AF Arrhythmia Burden: Percentage of time in AF
Tijdsspanne: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Global AF arrhythmia burden will be measured as percentage of time in AF measured during an 8-14-day monitoring period at the end of each time point as quantified by either clinically validated patch-based monitoring system or loop recorder. |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
|
AF Arrhythmia Burden: Duration of longest AF Arrhythmia Episode
Tijdsspanne: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Duration of the longest AF episode during the monitoring period will be quantified by either clinically validated patch-based monitoring system or loop recorder. |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
|
Weekly Step Counts
Tijdsspanne: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Weekly step counts measured by FitBit wearable device provided by the study |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
|
Weekly Exercise Minutes
Tijdsspanne: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Weekly exercise minutes measured by FitBit wearable device provided by the study |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Janice Y Chyou, MD, Icahn School of Medicine at Mount Sinai
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- STUDY-24-00464
- 24SCEFIA1249819 (Ander subsidie-/financieringsnummer: American Heart Association)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Not planning to share individual participant data. Aggregate data will be shared instead.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .